Saxagliptin

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
(New page: <applet load="" size="480" color="" frame="true" spin="on" Scene ="" align="right" caption="Saxaglyptin, better known as Onglyza, (___)"/> ===Better Known as: Onglyza=== * Marketed ...)
Line 12: Line 12:
===Pharmacokinetics===
===Pharmacokinetics===
-
<table style="background: cellspacing="0px" align="" cellpadding="0px" width="52%">
+
<table style="background: cellspacing="0px" align="" cellpadding="0px" width="45%">
<tr>
<tr>
<td style="width:100%; vertical-align:top;border-width:0px; border-style:inset">
<td style="width:100%; vertical-align:top;border-width:0px; border-style:inset">

Revision as of 10:17, 13 December 2010

Saxaglyptin, better known as Onglyza, ([[___]])

Drag the structure with the mouse to rotate

Better Known as: Onglyza

  • Marketed By:
  • Major Indication:
  • Drug Class:
  • Date of FDA Approval (Patent Expiration):
  • 2009 Sales:
  • Importance:
  • See Pharmaceutical Drugs for more information about other drugs and diseases.

Mechanism of Action

Pharmacokinetics

DPP4 Inhibitor Pharmacokinetics
Parameter Vildagliptin
(Galvus) 		Sitagliptin
(Januvia) 		Saxagliptin
(Onglyza)
Tmax (hr) 1.75 1-4 2
Cmax (ng/ml) 290 330 34
Bioavailability (%) 85 87 67
Protein Binding (%) 9 38 0
T1/2 (hr) 2-3 12.4 2.5
AUC (ng/ml/hr) 1610 3470 101
IC50 (nM) 3 18 50
Renal Clearance (L/h) 13.0 21.0 13.8
Volume Distribution (L) 71 198 151
Dosage (mg) 100 100 5
Metabolism Hydrolysis Hepatic (CYP3A4 & CYP2C8) Hepatic (CYP3A4)

For Pharmacokinetic Data References, see: References

References


Proteopedia Page Contributors and Editors (what is this?)

David Canner, Alexander Berchansky

Retrieved from "http://52.214.119.220/wiki/index.php/Saxagliptin"
Personal tools